Fig. 4: Pharmacological inhibition with novel selective TAK1 inhibitor HS-276 induces apoptosis in GSCs.
From: TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers
A, B Barplot of %Annexin V positive cells (A) and fold cell expansion (B) of U3013MG cells with knockout of TNFR pathway members upon 4 days treatment with DMSO or 3 µM HS-276. C, D Barplot of %Annexin V positive cells (C) and fold cell expansion (D) of U3013MG cells treated for 4 days with HS-276 or Takinib in combination with RIPK1 inhibitor Necrostatin-1s (Nec-1s). E Cumulative growth assay of U3013MG or G166 cells treated with DMSO, HS-276, or a combination of HS-276 and Nec-1s. F Barplot of fold cell expansion within 4 days of treatment with DMSO or 3 µM HS-276 in 4 different glioma stem cell lines (U3013MG, G166, U3017MG, and G14). G Barplot of fold cell expansion within 4 days of treatment with DMSO or 3 µM HS-276 in fetal neural stem cells (fNSC, U5). H Western blot of death complex IIb formation in GSCs upon treatment with TNFα and HS-276 for 2 or 4 h. I Barplot of cell viability relative to DMSO in U3013MG cells treated with indicated chemotherapeutic drugs in increasing concentrations alone or in combination with HS-276 for 4 days.
